Lauriane Eberst

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR

Souad Assaad, Virginie Avrillon, Marie‐Line Fournier et al. · European Journal of Cancer · 2020 · 124 citations · Full text

Medicine, Infectious Diseases, Oncology +6

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

Jean‐Pascal Machiels, Carlos Gomez‐Roca, Jean‐Marie Michot et al. · Journal for ImmunoTherapy of Cancer · 2020 · 78 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor

F.G.M. Verspoor, M.J.L. Mastboom, Gerjon Hannink et al. · Scientific Reports · 2019 · 77 citations · Full text

Medicine, Internal Medicine, Oncology +13

Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment

Pasi A. Jänne, Frédéric Bigot, Kyriakos P. Papadopoulos et al. · Molecular Cancer Therapeutics · 2023 · 56 citations

Medicine, Oncology, Pharmacology +15

The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers

Aurélien Voissière, Carlos Gomez‐Roca, Sylvie Chabaud et al. · Science Translational Medicine · 2024 · 54 citations

Medicine, Oncology, Pharmacology +17